PPT - Overall Survival and Progression-Free Survival PowerPoint Presentation - ID:4064400
Progression free survival and overall survival in patients treated with... | Download Scientific Diagram
Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect
Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review | International Journal of Gynecologic Cancer
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram
The Arts, Sciences and Medicine: Progression Free Survival (PFS)
Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom?
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Kaplan-Meier survival curves of progression-free survival and overall... | Download Scientific Diagram
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
Survival analysis in hematologic malignancies: recommendations for clinicians | Haematologica
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
Comparison of progression-free survival (A) or overall survival (B)... | Download Scientific Diagram
Progression-free survival (PFS) curve and overall survival (OS) curve... | Download Scientific Diagram
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
